Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT Trial) A Randomized, Double-blind, Placebo-controlled Seizure Prevention Clinical Trial for Infants With TSC

NCT02849457 is registered in ClinicalTrials.gov with Martina Bebin as lead sponsor.

NCT NCT02849457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02849457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT Trial) A Randomized, Double-blind, Placebo-controlled Seizure Prevention Clinical Trial for Infants With TSC
Lead sponsor
Martina Bebin
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
May 5, 2023
Enrollment
84 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

tuberous sclerosis complex